We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
We’re advancing muscle biology-driven treatments for diseases characterized by compromised muscle function, muscle weakness, and fatigue.
We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors.
Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.
Professor, Johns Hopkins
Cellular and Molecular Medicine
Director, Center for Molecular Cardiobiology